182 related articles for article (PubMed ID: 26657877)
41. Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights.
Rossi ED; Martini M; Bizzarro T; Capodimonti S; Cenci T; Lombardi CP; Pontecorvi A; Fadda G; Larocca LM
Cancer Cytopathol; 2015 Oct; 123(10):593-602. PubMed ID: 26230187
[TBL] [Abstract][Full Text] [Related]
42. Utility of the BRAF p.V600E immunoperoxidase stain in FNA direct smears and cell block preparations from patients with thyroid carcinoma.
Smith AL; Williams MD; Stewart J; Wang WL; Krishnamurthy S; Cabanillas ME; Roy-Chowdhuri S
Cancer Cytopathol; 2018 Jun; 126(6):406-413. PubMed ID: 29579361
[TBL] [Abstract][Full Text] [Related]
43. Immunohistochemistry is highly sensitive and specific for detecting the BRAF V600E mutation in papillary thyroid carcinoma.
Sun J; Zhang J; Lu J; Gao J; Lu T; Ren X; Duan H; Liang Z
Int J Clin Exp Pathol; 2015; 8(11):15072-8. PubMed ID: 26823846
[TBL] [Abstract][Full Text] [Related]
44. BRAF (V600E) mutation analysis on liquid-based cytology-processed aspiration biopsies predicts bilaterality and lymph node involvement in papillary thyroid microcarcinoma.
Rossi ED; Martini M; Capodimonti S; Lombardi CP; Pontecorvi A; Vellone VG; Zannoni GF; Larocca LM; Fadda G
Cancer Cytopathol; 2013 Jun; 121(6):291-7. PubMed ID: 23192956
[TBL] [Abstract][Full Text] [Related]
45. Dual priming oligonucleotide-based multiplex PCR analysis for detection of BRAFV600E mutation in FNAB samples of thyroid nodules in BRAFV600E mutation-prevalent area.
Kwak JY; Kim EK; Kim JK; Han JH; Hong SW; Park TS; Choi JR
Head Neck; 2010 Apr; 32(4):490-8. PubMed ID: 19672964
[TBL] [Abstract][Full Text] [Related]
46. BRAF(V600E) assessment by pyrosequencing in fine needle aspirates of thyroid nodules with concurrent Hashimoto's thyroiditis is a reliable assay.
Guerra A; Di Stasi V; Zeppa P; Faggiano A; Marotta V; Vitale M
Endocrine; 2014 Mar; 45(2):249-55. PubMed ID: 23775008
[TBL] [Abstract][Full Text] [Related]
47. Comparison of droplet digital PCR and direct Sanger sequencing for the detection of the BRAF
Wang Z; Sun K; Jing C; Cao H; Ma R; Wu J
J Clin Lab Anal; 2019 Jul; 33(6):e22902. PubMed ID: 31021028
[TBL] [Abstract][Full Text] [Related]
48. Immunohistochemistry as an accurate tool for evaluating BRAF-V600E mutation in 130 samples of papillary thyroid cancer.
Abd Elmageed ZY; Sholl AB; Tsumagari K; Al-Qurayshi Z; Basolo F; Moroz K; Boulares AH; Friedlander P; Miccoli P; Kandil E
Surgery; 2017 Apr; 161(4):1122-1128. PubMed ID: 27919446
[TBL] [Abstract][Full Text] [Related]
49. Role of ultrasonographic/clinical profile, cytology, and BRAF V600E mutation evaluation in thyroid nodule screening for malignancy: a prospective study.
Rossi M; Buratto M; Bruni S; Filieri C; Tagliati F; Trasforini G; Rossi R; Beccati MD; Degli Uberti EC; Zatelli MC
J Clin Endocrinol Metab; 2012 Jul; 97(7):2354-61. PubMed ID: 22535974
[TBL] [Abstract][Full Text] [Related]
50. BRAF V600E mutation and the Bethesda System for Reporting Thyroid Cytopathology of fine-needle aspiration biopsy for distinguishing benign from malignant thyroid nodules.
Sheng D; Yu X; Li H; Zhang M; Chen J
Medicine (Baltimore); 2021 Sep; 100(37):e27167. PubMed ID: 34664843
[TBL] [Abstract][Full Text] [Related]
51. Evaluation of the expression levels of BRAF
Tran TV; Dang KX; Pham QH; Nguyen UD; Trinh NTT; Hoang LV; Ho SA; Nguyen BV; Nguyen DT; Trinh DT; Tran DN; Orpana A; Stenman UH; Stenman J; Ho TH
BMC Cancer; 2020 May; 20(1):368. PubMed ID: 32357861
[TBL] [Abstract][Full Text] [Related]
52. Assessment of cellularity, genomic DNA yields, and technical platforms for BRAF mutational testing in thyroid fine-needle aspirate samples.
Dyhdalo K; Macnamara S; Brainard J; Underwood D; Tubbs R; Yang B
Cancer Cytopathol; 2014 Feb; 122(2):114-22. PubMed ID: 24150898
[TBL] [Abstract][Full Text] [Related]
53. [Value of the detection of
Zhao H; Guo HQ; Zhang ZH; Cao J; Zhao LL; Sun Y; Wang C; Xiao T
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2019 Jan; 54(1):18-22. PubMed ID: 30704164
[No Abstract] [Full Text] [Related]
54. The expression of monocarboxylate transporters in thyroid carcinoma can be associated with the morphological features of BRAF
Rossi ED; Bizzarro T; Granja S; Martini M; Capodimonti S; Luca E; Fadda G; Lombardi CP; Pontecorvi A; Larocca LM; Baltazar F; Schmitt F
Endocrine; 2017 May; 56(2):379-387. PubMed ID: 27484771
[TBL] [Abstract][Full Text] [Related]
55. The immunocytochemical expression of VE-1 (BRAF V600E-related) antibody identifies the aggressive variants of papillary thyroid carcinoma on liquid-based cytology.
Straccia P; Brunelli C; Rossi ED; Lanza P; Martini M; Musarra T; Lombardi CP; Pontecorvi A; Fadda G
Cytopathology; 2019 Sep; 30(5):460-467. PubMed ID: 30875124
[TBL] [Abstract][Full Text] [Related]
56. BRAF mutations in melanocytic lesions and papillary thyroid carcinoma samples identified using melting curve analysis of polymerase chain reaction products.
Hay R; MacRae E; Barber D; Khalil M; Demetrick DJ
Arch Pathol Lab Med; 2007 Sep; 131(9):1361-7. PubMed ID: 17824790
[TBL] [Abstract][Full Text] [Related]
57. BRAF mutation analysis in fine needle aspiration (FNA) cytology of the thyroid.
Jin L; Sebo TJ; Nakamura N; Qian X; Oliveira A; Majerus JA; Johnson MR; Lloyd RV
Diagn Mol Pathol; 2006 Sep; 15(3):136-43. PubMed ID: 16932068
[TBL] [Abstract][Full Text] [Related]
58. Reduction of false-negative papillary thyroid carcinomas by the routine analysis of BRAF(T1799A) mutation on fine-needle aspiration biopsy specimens: a prospective study of 814 thyroid FNAB patients.
Cañadas-Garre M; Becerra-Massare P; López de la Torre-Casares M; Villar-del Moral J; Céspedes-Mas S; Vílchez-Joya R; Muros-de Fuentes T; García-Calvente C; Piédrola-Maroto G; López-Nevot MA; Montes-Ramírez R; Llamas-Elvira JM
Ann Surg; 2012 May; 255(5):986-92. PubMed ID: 22504197
[TBL] [Abstract][Full Text] [Related]
59. Circulating BRAFV600E in the diagnosis and follow-up of differentiated papillary thyroid carcinoma.
Pupilli C; Pinzani P; Salvianti F; Fibbi B; Rossi M; Petrone L; Perigli G; De Feo ML; Vezzosi V; Pazzagli M; Orlando C; Forti G
J Clin Endocrinol Metab; 2013 Aug; 98(8):3359-65. PubMed ID: 23788690
[TBL] [Abstract][Full Text] [Related]
60. Increased CYP24A1 expression is associated with BRAF(V600E) mutation and advanced stages in papillary thyroid carcinoma.
Zou M; BinHumaid FS; Alzahrani AS; Baitei EY; Al-Mohanna FA; Meyer BF; Shi Y
Clin Endocrinol (Oxf); 2014 Jul; 81(1):109-16. PubMed ID: 24382015
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
